Literature DB >> 11154768

Timing of ketogenic diet initiation in an experimental epilepsy model.

S W Su1, M R Cilio, Y Sogawa, D C Silveira, G L Holmes, C E Stafstrom, D Silveira.   

Abstract

Following kainic acid (KA)-induced status epilepticus (SE), the ketogenic diet (KD) retards the development of epileptogenesis, with fewer spontaneous recurrent seizures (SRS) and less mossy fiber sprouting than rats on a normal diet. In this study, we investigated whether there is a critical period for initiation of the KD, in terms of the diet's effectiveness in reducing SRS. In addition, we investigated whether early treatment with the KD prevents the deficits in spatial learning and memory that ordinarily follow KA-induced SE. Young rats (P30) underwent KA-induced SE, followed by assignment to one of three treatment groups: control diet ('KA'), KD begun 2 days after SE ('KD2'), and KD begun fourteen days after SE ('KD14'). For 12 weeks following SE, rats were monitored by closed circuit video recording (12 h/wk) to detect SRS. KD2 rats had significantly fewer SRS than rats in the control or KD14 groups. On water maze testing to assess spatial learning and memory, KD2 rats had significantly poorer acquisition of place learning than control (KA alone) or KD14 rats. KD2 rats also failed to gain weight well. There was no difference between groups on routine histologic examination of the hippocampus. In summary, P30 rats placed on the KD 2 days after SE were relatively protected from recurrent seizures, but showed behavioral and physical impairment. Rats placed on the KD 14 days after KA-induced SE did not differ from controls with regard to spontaneous seizure rate.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11154768     DOI: 10.1016/s0165-3806(00)00130-9

Source DB:  PubMed          Journal:  Brain Res Dev Brain Res        ISSN: 0165-3806


  25 in total

1.  Purines and the Anti-Epileptic Actions of Ketogenic Diets.

Authors:  Susan A Masino; Masahito Kawamura; David N Ruskin; Jeremy Gawryluk; Xuesong Chen; Jonathan D Geiger
Journal:  Open Neurosci J       Date:  2010-01-01

2.  Dietary approaches to epilepsy treatment: old and new options on the menu.

Authors:  Carl E Stafstrom
Journal:  Epilepsy Curr       Date:  2004 Nov-Dec       Impact factor: 7.500

Review 3.  Neuroprotective and disease-modifying effects of the ketogenic diet.

Authors:  Maciej Gasior; Michael A Rogawski; Adam L Hartman
Journal:  Behav Pharmacol       Date:  2006-09       Impact factor: 2.293

Review 4.  Metabolism and epilepsy: Ketogenic diets as a homeostatic link.

Authors:  Susan A Masino; Jong M Rho
Journal:  Brain Res       Date:  2018-06-06       Impact factor: 3.252

Review 5.  Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis.

Authors:  Sharon S McDaniel; Michael Wong
Journal:  Neurosci Lett       Date:  2011-02-24       Impact factor: 3.046

Review 6.  Ketogenic diets, mitochondria, and neurological diseases.

Authors:  Lindsey B Gano; Manisha Patel; Jong M Rho
Journal:  J Lipid Res       Date:  2014-05-20       Impact factor: 5.922

7.  A ketogenic diet reduces long-term potentiation in the dentate gyrus of freely behaving rats.

Authors:  Jessica L Koranda; David N Ruskin; Susan A Masino; J Harry Blaise
Journal:  J Neurophysiol       Date:  2011-05-25       Impact factor: 2.714

8.  The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway.

Authors:  Sharon S McDaniel; Nicholas R Rensing; Liu Lin Thio; Kelvin A Yamada; Michael Wong
Journal:  Epilepsia       Date:  2011-03-03       Impact factor: 5.864

Review 9.  Progress in neuroprotective strategies for preventing epilepsy.

Authors:  Munjal M Acharya; Bharathi Hattiangady; Ashok K Shetty
Journal:  Prog Neurobiol       Date:  2007-12-08       Impact factor: 11.685

10.  The ketogenic diet suppresses the cathepsin E expression induced by kainic acid in the rat brain.

Authors:  Hyun Jeong Jeong; Hojeong Kim; Yoon-Kyoung Kim; Sang-Kyu Park; Dong-Won Kang; Dojun Yoon
Journal:  Yonsei Med J       Date:  2010-09       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.